Tysabri gets European backing at EMEA

Tysabri has taken one more step back to the global market, winning a recommendation from the European Medicines Agency that the multiple sclerosis drug be returned for restricted use. The EMEA advised the EU that Tysabri should be marketed for relapsing-remitting MS patients, delaying disability progression and reducing the rate of relapses. An FDA committee recommended that Tysabri be marketed as a first-line therapy for all MS sufferers. Tysabri was pulled early last year after it was linked to three cases of a rare brain disease. Elan's shares surged four percent on the news.

- here's the Marketwatch article for more information

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.